177 related articles for article (PubMed ID: 25672980)
1. Imaging active urokinase plasminogen activator in prostate cancer.
LeBeau AM; Sevillano N; Markham K; Winter MB; Murphy ST; Hostetter DR; West J; Lowman H; Craik CS; VanBrocklin HF
Cancer Res; 2015 Apr; 75(7):1225-35. PubMed ID: 25672980
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of [
Vangestel C; Thomae D; Van Soom J; Ides J; Wyffels L; Pauwels P; Stroobants S; Van der Veken P; Magdolen V; Joossens J; Augustyns K; Staelens S
Contrast Media Mol Imaging; 2016 Nov; 11(6):448-458. PubMed ID: 27558262
[TBL] [Abstract][Full Text] [Related]
3. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
4. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
5. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
Xie C; Jiang XH; Zhang JT; Sun TT; Dong JD; Sanders AJ; Diao RY; Wang Y; Fok KL; Tsang LL; Yu MK; Zhang XH; Chung YW; Ye L; Zhao MY; Guo JH; Xiao ZJ; Lan HY; Ng CF; Lau KM; Cai ZM; Jiang WG; Chan HC
Oncogene; 2013 May; 32(18):2282-91, 2291.e1-7. PubMed ID: 22797075
[TBL] [Abstract][Full Text] [Related]
6. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
van Rij CM; Sharkey RM; Goldenberg DM; Frielink C; Molkenboer JD; Franssen GM; van Weerden WM; Oyen WJ; Boerman OC
J Nucl Med; 2011 Oct; 52(10):1601-7. PubMed ID: 21865288
[TBL] [Abstract][Full Text] [Related]
7. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
8. Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of plasminogen activator inhibitor type 2 (PAI-2) forms.
Ranson M; Berghofer P; Vine KL; Greguric I; Shepherd R; Katsifis A
Nucl Med Biol; 2012 Aug; 39(6):833-9. PubMed ID: 22817872
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent.
Ides J; Thomae D; Wyffels L; Vangestel C; Messagie J; Joossens J; Lardon F; Van der Veken P; Augustyns K; Stroobants S; Staelens S
Nucl Med Biol; 2014 Jul; 41(6):477-87. PubMed ID: 24768145
[TBL] [Abstract][Full Text] [Related]
10. Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.
Pulukuri SM; Estes N; Patel J; Rao JS
Cancer Res; 2007 Feb; 67(3):930-9. PubMed ID: 17283123
[TBL] [Abstract][Full Text] [Related]
11. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells.
Festuccia C; Angelucci A; Gravina GL; Villanova I; Teti A; Albini A; Bologna M
Int J Cancer; 2000 Feb; 85(3):407-15. PubMed ID: 10652434
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft.
Billström A; Lecander I; Dagnaes-Hansen F; Dahllöf B; Stenram U; Hartley-Asp B
Prostate; 1995 Feb; 26(2):94-104. PubMed ID: 7531848
[TBL] [Abstract][Full Text] [Related]
13. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
Rabbani SA; Gladu J
Cancer Res; 2002 Apr; 62(8):2390-7. PubMed ID: 11956102
[TBL] [Abstract][Full Text] [Related]
14. Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.
Sevillano N; Bohn MF; Zimanyi M; Chen Y; Petzold C; Gupta S; Ralston CY; Craik CS
Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140562. PubMed ID: 33221341
[TBL] [Abstract][Full Text] [Related]
15. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.
Ustach CV; Kim HR
Mol Cell Biol; 2005 Jul; 25(14):6279-88. PubMed ID: 15988036
[TBL] [Abstract][Full Text] [Related]
16. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
17. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
18. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G
Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
20. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
